COL1A2 and metabolic dysfunction-associated steatotic liver disease: Statistical differences were found between patients with NAFLD compared to the control group for osteocalcin (n = 15 studies; SMD: −0.69; 95% CI: −0.73–−0.64; P=0.002), procollagen type I N-terminal propeptide (n = 5 studies; SMD: −0.40; 95% CI: −0.80−−0.00; P=0.049), and collagen type I cross-linked C-telopeptide (n = 7 studies; SMD: −0.16; 95% CI: −0.23−−0.09); P < 0.001).